This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alimera Sciences Reports Third Quarter 2010 Financial Results

ATLANTA, Nov. 4, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), today announced financial results for the third quarter ended September 30, 2010 and provided an update on the Company's progress.

"In August 2010, the FDA accepted our New Drug Application (NDA) for our lead product candidate, Iluvien®, for the treatment of diabetic macular edema (DME), and granted the NDA priority review status. Alimera could receive an action letter from the FDA by the end of this year," said Dan Myers, President and Chief Executive Officer of Alimera. "If the NDA is approved in the fourth quarter of 2010, we anticipate launching Iluvien® as early as the first quarter of 2011."

"We continue to believe Iluvien® could be the first ophthalmic drug approved in the United States for the treatment of DME, and that the addressable market for Iluvien® could reach $1 billion per year," said Mr. Myers. "Iluvien® is also being investigated in three Phase 2 pilot trials for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD and retinal vein occlusion."

Financial Highlights

Net loss for the quarter ended September 30, 2010 was $6.1 million, or $0.20 per common share, compared with a net loss of $7.5 million, or $4.89 per common share, for the quarter ended September 30, 2009.

Research and development expenses for the third quarter of 2010 totaled $3.3 million, compared to $3.6 million for the third quarter of 2009. General and administrative expenses were $1.3 million for the quarter ended September 30, 2010, compared to $0.8 million for the quarter ended September 30, 2009. Marketing expenses were $1.6 million for the third quarter of 2010, compared to $0.2 million for the third quarter of 2009.

As of September 30, 2010, Alimera had cash, cash equivalents and investments of $54.7 million, compared to $4.9 million as of December 31, 2009. In October 2010, the Company obtained a $32.5 million senior secured credit facility to help fund working capital requirements.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,118.71 +38.57 0.21%
S&P 500 2,121.25 +3.56 0.17%
NASDAQ 5,100.1650 +8.08 0.16%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs